Exhaled breath condensate cysteinyl leukotrienes and airway remodeling in childhood asthma: a pilot study

Respiratory Research

Table 1 Patients' characteristics

Number	29
Age (years)	10.2 (4–15)
Male, n	16
Atopic*, n	21
Duration of symptoms (years)	10.0 (5.0–12.0)
FEV₁ (% predicted)#	80 (64–91)
Treatment in previous 2 weeks
Inhaled steroid dosage (budesonide equivalent) (μg/day)	2000 (1000–2000)
Budesonide, n	7
Fluticasone, n	22
Oral and/or i.m. steroids, n	21
Long acting bronchodilator	28
Theophylline, n	1
Montelukast, n	14

Age data are expressed as mean (range). Other data are expressed as median (interquartile range) or absolute numbers (n).
*No data in 3 asthmatic children, ^# no data in five children who did not cooperate or could not withheld short-acting bronchodilator for 4 hours

ISSN: 1465-993X